❗ Breaking News❗ The BDFA is delighted to share that Tern Therapeutics, a biotechnology company based in the USA have entered into a global licensing agreement with REGENXBIO Inc. for RGX-381 and RGX-181. The company’s Chief Executive Officer, Alex Bailey and Chief Medical Officer, Christina Ohnsman were both instrumental to the development of the CLN2 programs in their previous roles at REGENXBIO. They will be using their experience and unique capabilities to initially focus on continuing the RGX-381 clinical trial in the UK at GOSH through to completion. The BDFA will be working in close contact with Tern Therapeutics, also continuing to work with REGENXBIO, and we are thrilled with the news of this licensing agreement, which will bring hope to the CLN2 community. We are pleased to share the company’s full press release, which contains a quote from Liz Brownnutt CEO of the BDFA, and a letter to the community from REGENXBIO. Tern Press Release: https://lnkd.in/etUqFUDY Regenxbio Letter to Community: https://lnkd.in/ewAcuXt7 Please get in touch with Liz if you have any questions - [email protected] 07745210212
Batten Disease Family Association
Non-profit Organizations
Together we will make a difference
About us
The Batten Disease Family Association CIO (BDFA) was formed in 1998 by a small group of parents of children with Batten Disease. The BDFA gained charity status in 2001, then became a charitable incorporated organisation (CIO) in 2024. The BDFA is committed to: Preserve and protect the health and promote the welfare of persons affected by all types of Neuronal Ceroid Lipofuscinosis (NCL) commonly known as Batten Disease To advance the education of professionals, carers and the general public on the subject of Batten Disease and its implications for the family To promote research into the management of Batten disease and to publish the useful results thereof and to support organisations promoting research into Batten disease.
- Website
-
http://www.bdfa-uk.org.uk
External link for Batten Disease Family Association
- Industry
- Non-profit Organizations
- Company size
- 2-10 employees
- Headquarters
- Shipley
- Type
- Nonprofit
- Specialties
- Education, Family Support, and Research Funding
Locations
-
Primary
PO Box 379
Shipley, BD18 9GE, GB
Employees at Batten Disease Family Association
Updates
-
🌎 Global Update - Clinical Trial in CLN5 disease update from Neurogene Inc. 🌎 Neurogene Inc. announced that its Phase 1/2 Trial of NGN-101 Gene Therapy for the treatment of CLN5 Batten disease is now fully enrolled (n=6), with plans to provide interim clinical data and a regulatory update in the first quarter of 2025. You can read more on our website, link below https://lnkd.in/epMqxpvn
-
-
🔶 Batten Disease Global Research Initiative Grants 🔶 Now Open for Expressions of Interest until AUGUST 30th Together, the BDFA, with our Global Research Initiative (GRI) partners, is delighted to announce the inaugural GRI Grant Round is now inviting Expressions of Interest. We seek to support the most promising research ideas worldwide that address key research questions and areas of unmet need in Batten disease. Submissions CLOSE AUGUST 30. To find out more about the Program and how to apply, please visit: https://lnkd.in/ecX2DiNs #BattenAdvocatesForACure #GlobalResearchInitiative #Research #BattenDisease Please contact Jo Nightingale if you have any queries, [email protected]
-
-
We're #hiring a new Trusts and Foundations Officer, remote role, United Kingdom. Apply today or share this post with your network.
-
Batten Disease Family Association reposted this
Today is International Batten Disease Awareness Day. Batten disease is a fatal, genetically inherited disorder affecting lysosomes which recycle material inside cells. Children are born with no signs there is anything wrong. Early in childhood their learning stagnates and regresses. They suffer from seizures, blindness and dementia. There is NO cure. Batten disease is ultra rare affecting about 1 in 100,000 live births. There are less than 200 children and young adults affected in this country. There are 13 genes that cause different types of Batten disease. Only one of these has a treatment to slow down progression - Brineura for CLN2 Batten disease. Please help us raise awareness by telling just one person about it today and if you can, please make a donation. Thank you.
-
-
🔸 IT’S INTERNATIONAL BATTEN DISEASE AWARENESS DAY 2024 🔸 Today is all about raising awareness of Batten disease with the global Batten community. Please join us by wearing orange and telling just one person about Batten disease today. Whilst we love Awareness Day to be a celebration of the incredible people in our community, we know this day can also be also be difficult for families affected by Batten disease and we send our love to you all.
-
-
🔸 International Batten Disease Awareness Day takes place on Sunday 9th June 2024 🔸 The Batten Disease Family Association (BDFA) are thrilled to have launched a ‘Text to Donate’ Awareness Campaign which is now LIVE! We would like to say a huge thank you to Beefy's Charity Foundation and Lord Ian 'Beefy' Botham for his continued support and for encouraging you to get involved with this year’s International Batten Disease Awareness Day. Details of how to donate are on the video below! Thank you and Together We WILL Make a Difference.
-
🔸🔸6 days to go until International Batten Disease Awareness Day 2024🔸🔸 It’s officially Batten Disease Awareness Week and the BDFA are thrilled to announce we have launched a ‘Text to Donate’ Awareness Campaign! Our Text to Donate campaign is live from TODAY🧡🧡 Details of how to donate are on the poster below. Please share this post and help us raise vital funds along with invaluable awareness. Thank you!!✨🧡
-
-
We’re endorsing @kidscharity new report, which reveals the huge gap in support faced by young people with SEND as they move from children’s to adults’ services. Read and share the report 👇 https://lnkd.in/emTab_ii
-
-
📌CLN2 Research News📌 Late last night we received news from the BDSRA that Latus Bio, an American biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), officially launched yesterday and announced a lead program for CLN2 Batten disease. You can find a link to the press release here: https://lnkd.in/etUZn5cf If you require any further information, please contact Jo ([email protected]).